STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3388 by analyst upside · 2026-08-12
PFE
Pfizer, Inc.
Healthcare · Market Cap $152B · P/E 35.0x
ANALYST PRICE TARGET
+7.6%
implied upside to consensus target
Current Price $26.62
Consensus Target $28.64
Bull Target $35.75
Bear Target $25.0
Analysts Covering 26
ANALYST CONSENSUS - HOLD
Strong Buy
2
Buy
7
Hold
15
Sell
2
52-Week Low $23.58
52-Week High $28.75
YTD Return +11.2%
FUNDAMENTALS
Market Cap $152B
P/E Ratio (TTM) 35.0x
Forward P/E 9.2x
EPS (TTM) $0.76
PEG Ratio 2.62
Dividend Yield 6.36%
Revenue (TTM) $63.7B
Profit Margin 6.8%
52-WEEK RANGE
52-Week Low $23.58
52-Week High $28.75
Current Price $26.62
Bear Target $25.0
Bull Target $35.75
● Now $26.62 ● Target $28.64
TRADING DATA
Avg Volume 42.0M
YTD Return +11.2%
Analyst Count 26
Consensus Hold
Upside to Target +7.6%
Last Updated 2026-08-12

ANALYST SUMMARY

Pfizer, Inc. (PFE) is currently trading at $26.62 with a Wall Street consensus price target of $28.64, implying potential upside of 7.6% over the next 12 months. 26 analysts currently cover PFE, with a consensus rating of Hold - 35% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $35.75, while the most cautious has a target of $25.0.

PFE operates in the Healthcare sector with a market capitalisation of $152B. The stock is up 11.2% year-to-date and is currently trading near the upper end of its 52-week range of $23.58 – $28.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PFE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital ↑ Upgrade
Underperform → Sector Perform 2026-06-10 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-04-29 Building track record
RBC Capital reit
Underperform → Underperform 2026-04-20 Building track record
CICC ● Initiated
Outperform 2026-04-16 Building track record
UBS - Reiterated
Neutral → Neutral 2026-04-13 33% win rate (6 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-04-10 Building track record
B of A Securities - Reiterated
Neutral → Neutral 2026-04-09 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-03-24 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
25/30
Consensus clarity
22/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →